The role of BCL-2 and BAK genes in chronic kidney disease and haemodialysis patients

Nour, Hanan; Zahran, Nariman; Elhamid, Samah Abd; Zahran, Manal; Raafat, Manar; Saeed, Asmaa El

doi:10.14302/issn.2572-5424.jgm-15-815

Cited by 2 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study investigated whether the circulating Bcl-2 in the CKD cats was significantly lower than those found in clinically normal age-matched cats. In agreement with previous studies, decreased Bcl-2 was also detected in other species with kidney problems ( 8 – 10 , 27 ). According to Zhang et al ( 8 ), Bcl-2 immunostaining in the kidney tissues of rats with UUO was less detectable than in the control group.…”

Section: Discussionsupporting

confidence: 93%

“…Consistent with a recent mouse study, Bcl-2 mRNA was substantially expressed in the UUO3 group but decreased in the UUO7 and UUO14 groups ( 9 ). Additionally, a prior investigation on human patients found that Bcl-2 levels were lower in patients with end-stage renal disease patients than in individuals with chronic kidney disease ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

“…However, more sample sizes in the previous studies reported the same trend as the present study. Forty patients with renal diseases possessed lower Bcl-2 gene expression in their blood samples than in 20 healthy individuals ( 10 ). As previously reported, there was no correlation between Bcl-2 positive cells and BUN or creatinine levels in glomerulonephritis patients ( 31 ).…”

Section: Discussionmentioning

confidence: 99%

“…Bcl-2 is an anti-apoptotic gene that has an inverse correlation with Bax, as shown in the previous study of unilateral ureteral obstruction (UUO) subjects, whereby it was shown that Bcl-2 levels will decrease during UUO ( 8 , 9 ). Bcl-2 levels of patients with end-stage renal disease, who were maintained on hemodialysis, underwent decreased expression when compared to the CKD group ( 10 ). A lack of Bcl-2 will increase the expression of Bax, which promotes the release of cytochrome C and mitochondrial outer membrane fragmentation.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of Bcl-2 as a marker for chronic kidney disease prediction in cats

et al. 2023

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a frequent condition in elderly cats. Bcl-2 is linked to kidney disease through the processes of apoptosis and fibrosis. The purpose of this study is to examine Bcl-2 levels in CKD and clinically healthy age-matched cats in order to evaluate the relationship between Bcl-2 levels, signalment, and blood parameters in cats with CKD. The circulating levels of Bcl-2 were determined using an immunoassay in twenty-four CKD cats and eleven clinically healthy age-matched cats by the utilization of the general linear model (GLM), Pearson correlation, principal component analysis (PCA), ROC curves, the Cox hazard model, and Kaplan–Meier survival analysis. These were all conducted in order to explore Bcl-2 levels and their connection with other variables. The Bcl-2 immunohistochemical intensity was graded in each glomerulus and tubulointerstitium. McNemar's test was performed in order to compare the expression of Bcl-2 in the two renal tissue sites. The circulating Bcl-2 of CKD cats was significantly lower than those of clinically healthy age-matched cats (P = 0.034). The presence of circulating Bcl-2 (P < 0.01) and the severity of CKD (P = 0.02) were both linked with the survival time of cats with CKD. The area under the curve (AUC) of Bcl-2 for detection of CKD was 0.723. In cats, decreased circulating Bcl-2 was associated with increased blood BUN, creatinine levels, and CKD severity. Bcl-2 protein expression was reduced in the renal tissues of CKD cats as the disease progressed, resulting in a decrease in their survival time. This study demonstrated that Bcl-2 may be effective in diagnosing feline CKD.

show abstract